Last updated on April 2019

Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs


Brief description of study

The purpose of this study is to assess the tolerability, adherence and efficacy of single tablet dolutegravir/abacavir/lamivudine antiretroviral therapy in people living with HIV with a history of injection drug use (IDU) switching from existing antiretroviral therapy (ART) or starting treatment after discontinuation of ART.

Detailed Study Description

Dolutegravir (DTG) is an integrase strand transfer inhibitor (INSTI) that supports once-daily dosing without the need for pharmacokinetic boosting and may be co-formulated with other antiretrovirals into a single-tablet regimen (STR). With people living with HIV with injection drug use (IDU) being more prone to unplanned antiretroviral therapy (ART) discontinuation and suboptimal adherence, DTG offers a high genetic barrier to resistance, a profile that reduces drug-drug interactions, with better tolerability and its availability as single tablet regimen (STR) combined with abacavir and lamivudine (ABC/3TC) is likely to improve adherence.

The aims of this study include:

  • To assess tolerability through self-reported adverse effects and directed symptom questionnaire
  • To determine change in number and severity of reported ART-related adverse effects from baseline to week 48 and 96
  • To determine change in health-related quality of life (HRQOL) from baseline to week 48 and 96
  • To determine change in frailty score from baseline to week 48 and 96
  • To determine the percentage of subject with unscheduled ART discontinuations/ interruptions over 96 weeks
  • To determine the estimated number of weeks of missed ART over 48 and 96 weeks of follow-up
  • To determine change from baseline of medication possession ratio (MPR) at 48 and 96 weeks or adherence score as measured by an antiretroviral therapy medication self-report form at the same time points
  • To determine the percentage of subjects with HIV RNA<40 copies/mL at 96 weeks
  • To determine change in genotypic resistance profiles in subjects experiencing virological failure
  • To determine change in CD4+ T-cell counts through 96 weeks
  • To determine change in bone mineral density through 96 weeks
  • To determine the number of subjects with any adverse and any serious adverse events (SAE) from baseline to week 96
  • To determine the number of subject with Grade 1 to 4 laboratory abnormalities from baseline to week 96

This is a prospective, single arm, open-label 96 weeks clinical trial. Study subjects will be followed for 96 weeks post enrolment, with regular clinical evaluations, laboratory evaluations, safety and adherence assessment, quality of life and bone mineral density (BMD) measured at regular intervals.

Clinical Study Identifier: NCT02659761

Find a site near you

Start Over